Effects of Pitavastatin on Adiponectin in Patients with Hyperlipidemia (original) (raw)
Article navigation
Research Articles| March 06 2008
aSecond Department of Internal Medicine, Kansai Medical University, Moriguchi,
Search for other works by this author on:
bDivision of Hematology, Kishiwada City Hospital, Kishiwada,
Search for other works by this author on:
cDepartment of Internal Medicine, Saiseikai Izuo Hospital, Osaka,
Search for other works by this author on:
aSecond Department of Internal Medicine, Kansai Medical University, Moriguchi,
Search for other works by this author on:
aSecond Department of Internal Medicine, Kansai Medical University, Moriguchi,
Search for other works by this author on:
aSecond Department of Internal Medicine, Kansai Medical University, Moriguchi,
Search for other works by this author on:
dDepartment of Cardiology, Baba Memorial Hospital, Sakai, and
Search for other works by this author on:
dDepartment of Cardiology, Baba Memorial Hospital, Sakai, and
Search for other works by this author on:
eDepartment of Brain Surgery, Tohou Kashiba Hospital, Kashiba, Japan
Search for other works by this author on:
aSecond Department of Internal Medicine, Kansai Medical University, Moriguchi,
Search for other works by this author on:
Pathophysiology of Haemostasis and Thrombosis (2008) 36 (1): 1–8.
Abstract
The effects of treatment with pitavastatin on inflammatory and platelet activation markers and adiponectin in 117 patients with hyperlipidemia were investigated to determine whether pitavastatin may prevent the progression of atherosclerotic changes in hyperlipidemic patients. Adiponectin levels prior to pitavastatin treatment in hyperlipidemic patients with and without diabetes were lower than levels in normolipidemic controls. Both total cholesterol and the low-density lipoprotein cholesterol decreased significantly after pitavastatin administration. Additionally, hyperlipidemic patients with or without type 2 diabetes exhibited a significant increase in adiponectin levels 6 months after pitavastatin treatment (diabetes: 3.52 ± 0.80 vs. 4.52 ± 0.71 µg/ml, p < 0.001; no diabetes: 3.48 ± 0.71 vs. 4.23 ± 0.82 µg/ml, p < 0.05). However, high-sensitivity C-reactive protein, platelet-derived microparticle and soluble P-selectin did not exhibit any differences before or after pitavastatin administration. Levels of adiponectin significantly increased after pitavastatin administration in the group of lower soluble P-selectin (soluble P-selectin before pitavastatin treatment <200 ng/ml). These results suggest that pitavastatin possesses an adiponectin-increasing effect in patients with hyperlipidemia and this effect is influenced by intensive platelet activation.
This content is only available via PDF.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
Sign in
Digital Version
Pay-Per-View Access
$39.00
1 Karger Article Bundle Token
$150
Rental
This article is also available for rental through DeepDyve. 